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Introduction
Despite the fact that shares of Tetracyclines and Ami-
noglycosides in acute-care hospitals hold the last position 
among other antibiotics subgroups, they remain an important 
component in patients’ antimicrobial treatment. Around 5% of 
patients admitted to acute-care hospitals acquire nosocomial 
infections [1, 2]. Antibiotical therapies treatment of severe 
acute respiratory  diseases (SARS), included tetracyclines 
(91.0%), aminoglycosides (83.3%), quinolones (79.2%); 18.8% 
of the patients received a combination of tetracyclines and 
aminoglycosides, while 11.5% received a combination of te-
tracyclines and quinolones, and 63.5% received a combination 
of tetracyclines, aminoglycosides and quinolones [3, 4]. The 
mortality rate of SARS worldwide is approximately 10.5%. The 
mortality rate of severe acute respiratory syndrome (SARS) 
patients admitted to the intensive care units (ICU) ranged 
from 5% to 67% [5, 6]. In international hospitals medium con-
sumption for Tetracyclines recorded 0.5-27-70,00 DDD/1000 
and for Aminoglycosides from 40.00 to 50,00 DDD/1000 or 
no more than 5% of all amount of antibiotics. Consumption 
in ICU for critically ill patients that received only gentamicin 
or amikacin is higher and varied between 38%-66% [7, 8, 9]. A 
higher consumption of Aminoglycosides from 25% to 45% of 
the total annual amount of antibiotics occurs in septic ortho-
traumotology department of EMI [10]. The above mentioned 
supposes surveillance, stringent consumption control and 
rational antibiotic prescription [11, 12, 13, 14].
The primary aim of the study was to evaluate institutional 
representative data on Tetracyclines and Aminoglycosides 
utilizationin in accordance to the World Health Organization 
(WHO) requirements, directed to determine value of Defined 
Daily Doses per 1000 Occupied-Bed Days (DDD/1000) [15, 
16].
Material and methods
For this study we used the data of a six-year (2009-2014) 
period, DDD/1000 consumption of Tetracyclines and Ami-
noglycoside antibacterials in Emergency Medicine Institute 
(EMI) in used rates are demonstrated.  EMI intencive care 
unit (ICU) – reanimation, therapy intensive care and “stro-
ke” intensive care departments, septic surgical and septic 
orhtotraumotology departments (SSOD) – which show the 
dynamics of consumption of antiinfectives for systemic use 
drugs, as classified by Anatomical Therapeutic Chemical 
(ATC), classification system of World Health Organization 
(WHO), indicated in grams and value indexes. Statistical, 
analytical, mathematical, comparative, logical and descriptive 
were used as the methods of study.
Results and discussion
For determining the number of DDD/1000 we used data 
about total annual consumption of Tetracycline’s and Amino-
glycosides antibacterials and the statistics data concerning the 
number of treated patients (only patients with health insurance 
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Abstract
Background: Tetracyclines and Aminoglycosides antimicrobials hold the last positions among all main antibiotic subgroups used yearly in hospitals. 
Nevertheless,without these medical remedies a qualified treatment of patients with different illnesses cannot be well organized or even would be impossible. 
Material and methods: For this study we used data of a six-year (2009-2014) period, in the Emergency Medicine Institute and their subdivisions where 
happened main consumption of antibiotics such as: Reanimation, Therapeutic intensive care, Therapeutic «stroke” intensive care, septic Surgery and 
septic Orthopedic-Traumatology departments - which show the consumption dynamics of Tetracyclines and Aminoglycosides antimicrobials use in 
grams and value indexes.
Results: The defined daily doses (DDD) per 1000 occupied-bed days (DDD/1000) in Emergency Medicine Institute in 2009 and 2014 for Tetracyclines 
registered an increase from 8.2 to 20.8 or a share of 1.24% and 4.48% from the total annual consumption. Aminoglycosides recorded a decrease from 
83.1 to 43.7 that represents a share of 12.55% and 9.42% from the total annual consumption. The same data in Intensive care departments recorded 
for Tetracyclines an increase from 3.61 to 53.98 DDD/1000 or 0.27% and 4.48% and respectively for Aminoglycosides from 494.49 to 134.4 or 15.12% 
and 11.16%. Septic departments recorded from 3.56 to 17.63 DDD/1000 or 0.57% and 3.44% and respectively for Aminoglycosides from 142.83 to 
137.04DDD/1000 or 22.64% and 26.77%.  In the mentioned period medium consumption in international hospitals of Tetracycline’s increased from 27.00 
to 70.00 DDD/1000 or by 2.59 times, and comparatively with the EMI in 2014 was higher by 3.36 times. Aminoglycosides consumption in international 
hospitals decreased from 50.00 to 40.00 DDD/1000 or by 20% and in 2014 year was similar with the data recorded in EMI.  Cost of DDD/1000 in 
Emergency Medicine Institute during 2009 and 2014 years, for Tetracyclines registered 1.89 and 5.57 lei, for Aminoglycosides respectively 461.19 and 
460.83 lei. In Intensive care departments costs recorded 0.98 and 14.44 lei and 2793.61 and 2634.39 lei, and in Septic departments 0.4 and 4.75 lei and 
536.61 and 329.23 lei respectively.
Conclusions: We found an increase in consumption of Tetracyclines DDD/1000 during the evaluated period, at the same time consumption in international 
hospitals in 2014 was in medium 70.00 DDD/1000 or 3.36 times more than 20.8 DDD/1000 recorded in EMI. Aminoglycosides in the evaluated period 
decreased in DDD/1000 consumption in EMI and international hospitals and in 2014 was around the same.
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and other free treated by the state categories of citizens). The total 
number of occupied bed/days in the institution was 188762 in 
2009, 191556 in 2010, 186246 in 2011, 199816 in 2012, 193019 
in 2013 and 187558 in 2014, and respectively for the correspon-
ding departments of EMI: reanimation intensive care unit (2009 
= 3990; 2010 = 6551; 2011 = 6985; 2012 = 9051; 2013 = 7384; 
2014 = 7361), therapeutical intensive care (2010 = 2922; 2011 = 
3327; 2012 = 3239; 2013 = 3407; 2014 = 3388), “stroke” intensive 
care (2013 = 2553; 2014 = 4193), septic surgical (2009 = 14030; 
2010 = 14212; 2011 = 12875; 2012 = 12372; 2013 = 12464; 2014 
= 12104), septic orthopedic-traumotology (2009 =10664; 2010 
= 10017; 2011 = 9540; 2012 = 10178; 2013 = 9701; 2014 = 9535) 
[17, 18, 19, 20].  Total Tetracyclines consumption in DDD/1000 
during 2009-2014 is shown in figure 1.
Tetracyclines consumption is characterised by the use 
of Doxycyclinum with 0.1gr defined daily doses.  As can be 
observed from figure 1 in the evaluated period was recorded 
an increase of the average consumption annual rate in septic 
orthopedic-traumotology department from 3.6 to 9.7, in septic 
surgical department from  1.41 to 25.6,  therapeutical intensive 
care department from 5.9 to 106.6 and reanimation depart-
ment from 1.35 to 1.36 DDD/1000. In the “stroke” intesive care 
department consumption of Tetracicynes was not registered 
at all. In figure 2 the total consumption of Aminoglicosides 
in DDD/1000 during 2010-2014 is shown.
Aminoglycosides antibacterials are presented with the use 
of Streptomycinum 1.0, Gentamycinum 0.2, Kanamycinum 
1.0 and Amikacinum 1.0 and respectively defined daily doses. 
Reanimation departament recorded the higher from 494.49 
to 219.13 DDD/1000 consumption with a decline by 55.69%. 
The consumption in septic orthotraumotology department 
was more stable and varied from 245.2 to 243.52 DDD/1000. 
The last third positions hold "stroke" intesive care depart-
ment where was recorded a decline from 206.03 to 124.73 
DDD/1000 or by 39.46%, followed by therapy intensive care 
department with an increase from 35.25 to 59.33 DDD/1000 
or by 68.31% and ended the list septic surgical department 
with a decrease from 40.45 in 2009 to 30.56 DDD/1000 or 
by 24.45%. The total consumption in intensive care units 
and septic departments in 2014 was 677.27 DDD/1000, from 
which the share of reanimation department represents 32.36%, 
Therapy intensive care department 8.76%, "stroke" intensive 
care department 18.42%, septic surgical department 4.51% 
and septic orthotraumotology department 35.96%.
In table 1 comparison of average DDD/1000 consumption 
of Tetracyclines and Aminoglycosides antibacterials in inten-
sive care and septic departments of EMI is shown.
Table 1
Average DDD/1000 consumption of Tetracyclines  
and Aminoglycosides antibacterials in intensive care  
and septic departments of E
 Units 2009 2010 2011 2012 2013 2014
 Tetracyclines
ICU 3.61 53.98
SSOD 3.56 2.7 5.13 10.54 24.88 17.63
EMI 8.2 26.8 15.1 7.1 13.5 20.8
Aminoglycoside antibacterials
ICU 494.49 85.63 174.79 292.74 222.19 134.4
SSOD 142.83 74.13 187.45 93.54 157.84 137.04
EMI 83.1 37.60 76.90 103.20 112.30 43.70
Total antibiotics consumption in EMI
EMI 662.4 558.2 662.1 542.4 546.9 464.1
Fig. 1.  Total Tetracyclines consumption in DDD/1000 during 2009–2014.
Fig. 2.  Total consumption of Aminoglycosides in DDD/1000.
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Table 2
Total DDD/1000 consumption of Tetracyclines and Aminoglycosides  
in EMI and some international acute hospitals
Total DDD/1000 consumption of Tetracyclines in international acute hospitals
  2009 2010 2011 2012 2013 2014
Emergency Medicine Institute 8.20 26.80 15.10 7.10 13.50 20.80
Large acute Australian public hospitals [21] 27.00 41.50 52.00 60.00 60.00 70.00
The number of hospitals 16 18 22 32 42 51
Medium acute Australian public hospitals 52.00 42.50 42.00 61.50 71.00 80.00
The number of hospitals 9 9 10 13 24 26
South Australian metropolitan hospitals 40.00 38.70 37.60 41.70 37.20
SAAUSP 37.2, NAUSP 44.00, NETHMAP 18.00 in 2013; SWEDRES 54.00, DANMAP 15.80 in 2012 [21]
Total DDD/1000 consumption of Aminoglycosides in international  acute hospitals
  2009 2010 2011 2012 2013 2014
Emergency Medicine Institute 83.1 37.60 76.90 103.20 112.30 43.70
Large acute Australian public hospitals [22] 50.00 50.00 45.00 43.00 43.00 40.00
The number of hospitals 16 18 22 32 42 51
Medium acute Australian public hospitals 53.00 58.00 51.00 50.00 42.00 38.00
The number of hospitals 9 9 10 13 24 26
South Australian metropolitan hospitals 65.50 66.50 64.20 58.70 55.50
SAAUSP 55.5, NAUSP 42.1, NETHMAP 39.00 in 2013 and  SWEDRES 12.00, DANMAP 21.4 in 2013 [22]
Fig. 3.  Total value cost of Tetracyclines use per DDD/1000 in lei.
As can be seen from table 1 average DDD/1000 consump-
tion of Tetracyclines antibacterials in intensive care and septic 
departments in the evaluated period increased respectively by 
14.9 (53.98:3.61) and 4.9 (17.63:3.56) times, and totally for 
the institution by 2.4 (20.8:8.2) times. For Aminoglycoside 
the data conversely recorded a decrease by 3.6 (494.49:134.4) 
times and 5% (142.83:137.04), and totally for the institution 
by 1.9 (83.1:43.7) times. In table 2 is shown Tetracyclines and 
Aminoglycosides antimicrobial use in EMI and many different 
international surveillance programs, such as: SAAUSP (South 
Australian Antimicrobial Utilization Surveillance Program), 
NAUSP (National Antibiotic Utilization Surveillance Pro-
gram), NETHMAP (Netherlands Monitoring Antimicrobial 
Resistance Program), SWEDRES (Swedish Antimicrobial 
Utilization and Resistance in Human Medicine), DANMAP 
(Danish Integrated Antimicrobial Resistance Monitoring and 
Research Program).
From table 2 as one can see in the evaluated period the 
total consumption of Tetracycline’s in large acute international 
public hospitals increased by 2.59 (70:27) times and respecti-
vely in EMI by 2.5 times, at the same time in 2014 these data 
in EMI were less than recorded in international large acute 
hospitals in medium by 3–4 times. Aminoglycosides in EMI 
registered an instable consumption, nevertheless, in the end 
of the evaluated period comparatively with international acute 
hospitals recorded in medium the similar data.
In fig. 3 the total DDD/1000 Tetracyclines consumption 
in lei during 2010-2014 is shown.
As we can see from figure 3 the average consumption 
annual rate per DDD/1000 in value indexes
• for Tetracyclines in all departments recorded an incre-
ment, even so these data are low in the beginning and 
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the end of the evaluated period for therapeutic intensive 
care department registered
• 1.59 and 28.51 lei, septic surgical department – 4.54 and 
6.92 lei, septic orthotramotology department – 0.81 and 
2.58 lei as to reanimation department – 0.37 and 0.36 lei.
The value cost of Aminoglycosides antibacterials use per 
DDD/1000 in lei is presented in figure 4.
As can be observed from figure 4 during the evaluated pe-
riod the main value cost of DDD/1000 recorded reanimation 
department from 5587.22 to 5879.70 lei, with the highest re-
sults in 2013 of 12780 lei and consequently the second position 
holds «stroke” intensive care department from 2950.30 lei to 
1468.60 lei and respectively therapy intensive care department 
from 1980.60 to 554.87 lei, with the highest results in 2011 of 
6160.50 lei is placed on the third position. The last position, 
is divided between septic orthotraumotology department 
with the cost of DDD/1000 from 670.63 to 459.92 lei, with 
the higher cost of 1395.50 lei in 2011, and respectively septic 
surgical department from 402.58 to 198.54 lei and the higher 
cost of 824.77 lei in 2011. 
In table 3 is presented the medium cost DDD/1000 of Te-
tracyclines and Aminoglycosides for ICU and SSOD in lei. To 
determine the medium cost of DDD/1000 was counted total 
cost of DDD/1000 separately for ICU and SSOD and divided 
by the number of these departments (3 and respectively 2) in 
the evaluated period.
Table 3
Cost of medium DDD/1000Tetracyclines and 
Aminoglycosides in lei 
 Tetracyclines
 2009 2010   2011  2012 2013 2014
ICU 0.98 14.44
SSOD 0.4 0.61 11.45 2.96 6.89 4.75
EMI 1.89 6.13 3.76 1.98 3.73 5.57
 Aminoglycosides
ICU 2793.6 2126.8 5308.7 6297.5 6036.3 2634.39
SSOD 536.61 419.62 1110.2 845.63 801.64 329.23
EMI 461.19 286.64 664.02 716.28 812.72 460.83
As we can see from table 3 in the evaluated period the 
medium cost of DDD/1000 for Tetracyclines in 2014 recorded 
for SSOD 4.75 lei, or less by 3 times than cost of 14.44 lei in 
ICU and respectively 329.23 lei cost for Aminoglycosides in 
SSOD in 2014 or less by 8 times than 2634.39 lei recorded ICU.
Conclusions
1. Consumption of Tetracyclines in DDD/1000 in the evalua-
ted period increased in all evaluated departments of EMI as 
follows: therapeutical intensive care department from 5.9 to 
106.6, septic surgical department from 1.41 to 25.6, septic 
orthopedic-traumotology department from 3.6 to 9.7 and 
reanimation departmet from 1.35 to 1.36 DDD/1000, that 
reprezents respectively a share from the total departments 
consumption of 142.6 DDD/1000 in 2014 of 74.3%, 17.9%, 
6.8% and 0.9%. Despite entire institution growth from 8.2 
to 20.8 DDD/1000, the difference of consumption is more 
than 3 - 4 times comparatively with 70 – 80 DDD/1000 
recorded in international hospitals. 
2. The decrease of the value cost of DDD/1000 in lei for 
Tetracyclines in the end of evaluated period was recorded 
for therapeutic intensive care department 28.51 lei, septic 
surgical department – 6.92 lei, septic orthotramotology 
department – 2.58 lei as to reanimation – 0.36 lei, when for 
the entire institution – 5.57 lei.
3. Consumption of Aminoglycosides in the evaluated period 
was recorded in all departments as follows:   reanimation 
department from 494.49 to 219.13 DDD/1000, septic ortho-
traumotology department from 245.2 to 243.52 DDD/1000, 
"stroke" intensive care department from 206.03 to 124.73 
DDD/1000, therapy intensive care department from 35.25 
to 59.33 DDD/1000 and from 40.45 to 30.56 DDD/1000 
septic Surgical department, that represents respectively a 
share from the total departments consumption of 677.27 
DDD/1000 in 2014 of 32.36%, 35.96%, 18.42%, 8.76% and 
4.51% respectively. An unstable consumption recorded in 
EMI from 83.1 at the beginning to 43.7 DDD/1000 in the 
end of the evaluated period, which in the medium is similar 
comparatively to international acute hospitals records. 
4. The decreased records of value cost of DDD/1000 in lei for 
Aminoglycosides in 2014 were for reanimation department 
5879.70 lei, „stroke” intensive care department – 1468.60 
lei, therapy intensive care department – 554.87 lei, septic 
orthotraumotology department – 459.92 lei, septic surgical 
department – 198.54 lei.
5. The average DDD/1000 consumption of Tetracyclines in 
intensive care departments and septic departments during 
Fig. 4.  Value cost of Aminoglycosides antibacterial for systemic use per DDD/1000 in lei.
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the evaluated period increased respectively by 14.9 and 4.9 
times, and totally for institution by 2.4 times. For Amino-
glycoside the data conversely recorded a decrease by 3.6 
times and 5%, and for the total institution by 1.9 times.
6. In 2014 the medium cost of DDD/1000 for Tetracyclines in 
SSOD recorded 4.75 lei, or less by 3 times than cost of 14.44 
lei in ICU and respectively of 329.23 lei for Aminoglycosides 
in SSOD or less by 8 times than 2634.39 lei recorded in ICU. 
7. According to some scientific researches antibiotical thera-
pies treatment of severe acute respiratory  diseases (SARS), 
included tetracyclines (91.0%), aminoglycosides (83.3%), 
quinolones (79.2%); 18.8% of the patients received a com-
bination of tetracyclines and aminoglycosides, while 11.5% 
received a combination of tetracyclines and quinolones, and 
63.5% received a combination of tetracyclines, aminogly-
cosides and quinolones.
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